Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.47 |
| ▸ | CTSB | P07858 | 9/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860813 | 0.93 | CTSK (0.44) | CTSKCTSBCTSSCTSLBACE1 | |
| SCHEMBL30522100 | 0.89 | CTSK (0.54) | CTSKCTSBCTSSCTSLBACE1 | |
| SCHEMBL23893529 | 0.87 | CTSL (0.54) | CTSKCTSBCTSSCTSL | |
| SCHEMBL31388652 | 0.86 | CTSK (0.53) | CTSKCTSBCTSSCTSLBACE1 | |
| SCHEMBL29860969 | 0.84 | CTSK (0.39) | CTSKCTSBCTSSCTSLBACE1 | |
| SCHEMBL29861086 | 0.83 | CTSK (0.41) | CTSKCTSBCTSSCTSLBACE1 | |
| SCHEMBL29860893 | 0.83 | CTSK (0.38) | CTSKCTSBCTSSCTSLBACE1 | |
| SCHEMBL29973019 | 0.81 | BACE1 (0.38) | CTSKCTSBCTSSCTSLBACE1 | |
| SCHEMBL29861077 | 0.81 | CTSB (0.48) | CTSKCTSBCTSSCTSL | |
| SCHEMBL30763326 | 0.80 | CTSK (0.37) | CTSKCTSBCTSSCTSLBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732002-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732002-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | VIP, PEPD, MLN | CTSK 423/4885CTSB 348/4885CTSS 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.